drugset / Trial / NCT01944800

Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome

NCT01944800

RandomizedParallel-groupSingle-blindTreatment

Summary

Aim of the randomized, open-label, multicenter ISAR-REACT 5 trial is to assess whether ticagrelor is superior to prasugrel in patients with acute coronary syndrome and planned invasive strategy in terms of clinical outcomes.

Timeline

Start
2013-09-15
Primary completion
2019-07
Completion
2021-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prasugrel Small molecule 5 mg
Comparator Prasugrel Small molecule 10 mg
Subject Ticagrelor Small molecule 180 mg